A Single-arm, Open-label, Multi-center, Phase IV Trial to Evaluate the Reactogenicity, Safety, and Immunogenicity of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a post-approval condition imposed by the Indian regulatory authorities (CDSCO) for this age group in India.

Start Date14 Dec 2023

Sponsor / Collaborator

GSK Plc

NCT05734040 / CompletedPhase 2

Phase 2a, Randomized, Double-blind (Double-dummy), Double Placebo-controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and Quadrivalent Inactivated Influenza Vaccines (QIVs: Fluarix Tetra and Afluria Quad) Given Intramuscularly as 2 Separate Injections Into Opposite Arms, in Comparison to the Concomitant Administration of Quadrivalent Inactivated Influenza Vaccines and Placebo, and OVX836 and Placebo Given the Same Way in Healthy Subjects Aged 18 to 60 Years.

The present study OVX836-006 aims principally to:
Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e. as two separate concomitant injections into opposite arms;
Introduce an additional representative brand of Quadrivalent Inactivated Influenza Vaccines ;
Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the Hemagglutinin response;
Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the nucleoprotein response;
Evaluate the absolute vaccine efficacy of OVX836 compared to placebo in order to corroborate the efficacy signals previously detected in the OVX836 previous studies;
Evaluate the combined vaccine efficacy of OVX836 + Quadrivalent Inactivated Influenza Vaccines versus OVX836 + placebo, and versus double placebo.

Start Date10 May 2023

Sponsor / Collaborator

Osivax SASStartup

[+2]

NCT05170399 / RecruitingPhase 4IIT

Vaccine Responses in Patients With B Cell Malignancies

Background:
People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers.
Objective:
To learn how well vaccines work in people who have certain types of blood cancers.
Eligibility:
Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, or certain non-Hodgkin lymphomas.
Design:
Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and shingles. They can choose which vaccines they receive. They will give a blood sample before they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may give an optional blood sample with the second vaccine dose. About 4 weeks after they finish each vaccine series, they will give another blood sample. They will have 2-3 study visits per vaccine.
Participants may receive a booster dose for some vaccines. The booster dose is optional. They will give another blood sample with the booster dose.
Participants will have pregnancy tests, if needed.
Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks.
Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood samples are optional.
Participation will last for up to 5 years after each vaccine series is received.

Start Date14 Sep 2022

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

100 Translational Medicine associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

100 Patents (Medical) associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

160

Literatures (Medical) associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

12 Oct 2023·Vaccines

Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3-8 Years.

Article

Author: Li, Lanshu ; Tang, Rong ; Wang, Jianfeng ; Pan, Hongxing ; Yang, Wanqi ; Shi, Yunfeng ; Hu, Yuansheng ; Zhao, Chenyan ; Chu, Kai ; Li, Xiaoyu ; Xu, Li

Two doses of the inactivated influenza vaccine (IIV) are generally recommended for children under 9 years old. This study assessed the necessity for a second dose of quadrivalent IIV (IIV4) in children aged 3-8 years. In this randomized, open-label, paralleled-controlled study, 400 children aged 3-8 years who were vaccine-unprimed were randomly assigned at a 1:1 ratio to receive a two-dose (Group 1) or one-dose (Group 2) regimen of IIV4, and 200 who were vaccine-primed received one dose of IIV4 (Group 3). A serum sample was collected before and 28 days after the last dose to determine the hemagglutination inhibition (HI) antibody level. Adverse events were collected within 28 days after each dose. One-dose or two-doses of IIV4 were well tolerated and safe in children aged 3-8 years, and no serious adverse events related to the vaccine were reported. The seroconversion rates (SCRs) of HI antibody ranged from 61.86% to 95.86%, and the post-vaccination seroprotection rates (SPRs) were all >70% in three groups against the four virus strains. The two-dose regimen in vaccine-unprimed participants (Group 1) achieved similar SPRs in comparison with the one-dose in the vaccine-primed group (Group 3), and the SPRs in Group 1 and Group 3 were higher in vaccine-unprimed participants of the one-dose regimen (Group 2). The present study supports the recommendations of a two-dose regimen for IIV4 use in children aged 3-8 years.

26 Sep 2023·Vaccines

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.

Article

Author: Versage, Eve ; Zhang, Qiuhong ; Molrine, Deborah ; Meyer, Jay ; Hohenboken, Matthew ; Poder, Airi ; Heymer, Peter ; Oberije, Janine ; Isakov, Leah

Adults aged 50-64 years have a high incidence of symptomatic influenza associated with substantial disease and economic burden each year. We conducted a randomized, controlled trial to compare the immunogenicity and safety of an adjuvanted quadrivalent inactivated influenza vaccine (aIIV4; n = 1027) with a nonadjuvanted standard dose IIV4 (n = 1017) in this population. Immunogenicity was evaluated on Days 22, 181, and 271. On Day 22, upper limits (UL) of 95% confidence intervals (CI) for geometric mean titer (GMT) ratios (IIV4/aIIV4) were <1.5 and 95% CI ULs for the difference in seroconversion rate (SCR IIV4 - aIIV4) were <10% for all four vaccine strains, meeting primary endpoint noninferiority criteria. Protocol-defined superiority criteria (95% CI ULs < 1.0) were also met for A(H1N1) and A(H3N2). Immune responses following aIIV4 vaccination were more pronounced in persons with medical comorbidities and those not recently vaccinated against influenza. Safety data were consistent with previous studies of MF59 adjuvanted seasonal and pandemic influenza vaccines. These findings support the immunological benefit of aIIV4 for persons aged 50-64 years, especially those with comorbidities.

01 Aug 2023·Open forum infectious diseases

Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults ≥65 Years.

Article

Author: Haag, Mendel ; Sardesai, Aditya ; Toro-Diaz, Hector ; Taylor, Alexandra ; McGovern, Ian

Background:

The MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3) is designed to overcome immunosenescence and enhance vaccine responses in older adults. We expanded on the Centers for Disease Control and Prevention (CDC) modeling method to estimate the number of additional influenza-related outcomes averted with aIIV3 versus generic quadrivalent inactivated influenza vaccine (IIV4) in adults ≥65 years over 3 influenza seasons (2017-2018 to 2019-2020) in the United States.

Methods:

A static compartmental model was developed based on an existing CDC model with 2 previously recommended calculation methods that increased the accuracy of the model in providing estimates of burden averted. Model inputs included vaccine effectiveness, vaccine coverage, population counts, and disease burden estimates. Additional burden averted (symptomatic cases, outpatient visits, hospitalizations, intensive care unit [ICU] admissions, and deaths) was expressed as total incremental cases averted between the vaccines. Sensitivity analyses tested the resilience of the model results to uncertainties in model inputs.

Results:

The model estimated that vaccination with aIIV3 versus IIV4 would avert 2.24 times as many symptomatic cases, outpatient visits, hospitalizations, ICU stays, and deaths during 2017-2018; the burden averted in 2018-2019 and 2019-2020 with aIIV3 would be 3.44 and 1.72 times that averted with IIV4, respectively. Disease burden estimates and relative vaccine effectiveness of aIIV3 had the greatest impact on model estimates.

Conclusions:

Over 3 influenza seasons, the model estimated that aIIV3 was more effective than IIV4 in averting influenza-related outcomes, preventing 1.72 to 3.44 times as many influenza illnesses with proportionate decreases in related healthcare use and complications.

News (Medical) associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

11 Jun 2024

·pmlive.com

Moderna shares positive late-stage results for COVID-19/flu combination vaccine

Moderna has shared positive late-stage results for its investigational combination vaccine against influenza and COVID-19. The ongoing phase 3 trial has been evaluating the candidate, mRNA-1083, in two age-group cohorts of approximately 4,000 adults each. One cohort has been comparing mRNA-1083 to Sanofi’s enhanced Fluzone HD flu vaccine co-administered with Moderna’s standalone COVID-19 vaccine Spikevax in adults aged 65 years and older, while the other has been comparing the combination vaccine to GSK’s standard dose Fluarix flu vaccine in adults aged 50 to 64 years, also given alongside Spikevax. The immune responses from a single dose of mRNA-1083 were found to be non-inferior versus the co-administered comparators, GSK said, adding that mRNA-1083 elicited statistically significantly higher immune responses against three influenza virus strains and against SARS-CoV-2 in both groups. The company also reported that mRNA-1083 showed an acceptable tolerability and safety profile, with the majority of solicited adverse reactions consistent with the vaccines used in the trial. The combined vaccine approach could alleviate the impact of both COVID-19 and flu while offering a combined administration, potentially simplifying immunisation practices for healthcare providers as well as patients. Stéphane Bancel, Moderna’s chief executive officer, said: “Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses.” Bancel added that Moderna is the only company with positive phase 3 data for a flu/COVID-19 combination vaccine. The company said it is planning to present the phase 3 data for mRNA-1083 at an upcoming medical conference and will “engage with regulators on next steps”. The readout comes just over a week after Moderna’s respiratory syncytial virus (RSV) vaccine was approved by the US Food and Drug Administration to protect adults aged 60 years and older against lower respiratory tract disease caused by RSV infection. The vaccine, mRESVIA, is now the only RSV vaccine available in single-dose pre-filled syringes and the first mRNA vaccine to receive approval for a disease other than COVID-19.

VaccinePhase 3Clinical ResultDrug ApprovalmRNA

10 Jun 2024

·firstwordpharma.com

Moderna’s flu, COVID-19 combo vaccine passes key test

Moderna’s combination vaccine against influenza and COVID-19 met the primary endpoints of a late-stage study, eliciting a higher immune response than comparator shots used in the trial. CEO Stéphane Bancel said on Monday "we are very delighted about the results,” as they position Moderna as “the only company with a positive Phase III flu and COVID combination vaccine.”The jab, dubbed mRNA-1083, comprises components of Moderna’s vaccine candidate for seasonal flu mRNA-1010 and its next-generation COVID-19 shot mRNA-1283.The study consisted of one group of adults 65 years and older who received mRNA-1083 or separate doses of Sanofi’s flu vaccine Fluzone HD and Moderna’s currently licensed COVID-19 jab Spikevax. The second group, comprising adults ages 50 to 64, received mRNA-1083 or separate shots of GSK’s flu vaccine Fluarix and Spikevax.Results showed that the immune response from a single dose of mRNA-1083 was non-inferior to the co-administered vaccines, eliciting significantly higher immune responses against the H1N1, H3N2 and B/Victoria flu strains, as well as against SARS-CoV-2. Bancel suggested that the better performance compared to Spikevax was likely because mRNA-1083 has been designed to combat more recent variants of the coronavirus.Moderna added that mRNA-1083 had an acceptable tolerability and safety profile in the study, with the majority of adverse reactions being Grade 1 or 2 injection-site pain, fatigue, myalgia and headache. The company plans to present the data at an upcoming medical conference and engage with regulators on next steps. Meanwhile, Bancel suggested that mRNA-1083 could be launched next year and be more widely available in 2026.Earlier this year, Moderna reached an agreement to bring in external funding of up to $750 million from Blackstone Life Sciences to support development of its mRNA-based flu vaccines, including mRNA-1010, as well as other combination shots to provide protection against flu, respiratory syncytial virus (RSV) and COVID-19. The drugmaker recently gained FDA approval for its RSV vaccine mRESVIA, marking the first step in its commercial efforts beyond COVID-19.For further analysis, read Spotlight On: Will Moderna’s RSV vaccine help to deliver on the promise of mRNA?

VaccineClinical ResultmRNAPhase 3Drug Approval

10 Jun 2024

·www.biospace.com

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial. "Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses," said Stéphane Bancel, Chief Executive Officer of Moderna. "Moderna is the only company with a positive Phase 3 flu and COVID combination vaccine. Building on the momentum of positive Phase 3 data across our respiratory portfolio, we continue to address significant unmet medical needs and advance public health." mRNA-1083 comprises components of mRNA-1010, Moderna's vaccine candidate for seasonal influenza, and mRNA-1283, Moderna's next-generation COVID-19 vaccine candidate. Each investigational vaccine has independently demonstrated positive Phase 3 clinical trial results. The ongoing Phase 3 clinical trial (ClinicalTrials.gov Identifier:NCT06097273) is a randomized, observer-blind, active control study evaluating the safety, reactogenicity and immunogenicity of mRNA-1083 in two independent age group cohorts of approximately 4,000 adults each. One cohort, consisting of adults 65 years and older, compared mRNA-1083 to co-administered Fluzone HD®, an enhanced influenza vaccine, and Spikevax®, Moderna's currently licensed COVID-19 vaccine. The other cohort of adults 50 to 64 years of age compared mRNA-1083 to co-administered, Fluarix®, a standard dose influenza vaccine, and Spikevax. The immune responses from a single dose of mRNA-1083 were found to be non-inferior versus the co-administered, routinely recommended, licensed comparators. In both age cohorts, mRNA-1083 also elicited statistically significantly higher immune responses against three influenza virus strains (H1N1, H3N2, and B/Victoria) and against SARS-CoV-2. In the 65 years and older cohort, overall Geometric Mean Ratios (GMRs) of the mRNA-1083 group compared to the Fluzone HD group for the influenza strains were 1.155 (95% CI: 1.094, 1.220) for A/H1N1, 1.063 (95% CI: 1.007, 1.122) for A/H3N2 and 1.118 (95% CI: 1.070, 1.167) for B/Victoria. The GMR of mRNA-1083 compared to Spikevax for the SARS-CoV-2 variant Omicron XBB.1.5 was 1.641 (95% CI: 1.526, 1.765). In the 50 to 64 years of age cohort the GMRs of the mRNA-1083 group compared to the Fluarix group for the influenza virus strains were 1.414 (95% CI: 1.333, 1.500) for A/H1N1, 1.380 (95% CI: 1.310, 1.454) for A/H3N2, and 1.216 (95% CI: 1.163, 1.270) for B/Victoria. The GMR of mRNA-1083 compared to Spikevax for the SARS-CoV-2 variant Omicron XBB.1.5 was 1.308 (95% CI: 1.219, 1.404). Immunogenicity was also tested against the B/Yamagata strain of influenza and mRNA-1083 met non-inferiority criteria in both age cohorts. Due to the disappearance of the B/Yamagata lineage from circulation, WHO has recommended a trivalent influenza vaccine composition without B/Yamagata for 2024/2025 vaccines. mRNA-1083 showed an acceptable tolerability and safety profile. The majority of solicited adverse reactions were grade 1 or 2 in severity and consistent with the licensed vaccines used in the trial. The most commonly solicited adverse reactions were injection site pain, fatigue, myalgia and headache. Moderna plans to present the Phase 3 clinical data for mRNA-1083 at an upcoming medical conference as well as submit it for publication. The Company will engage with regulators on next steps. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Spikevax® is a registered trademark of Moderna. Fluzone HD® is a registered trademark of Sanofi Pasteur. Fluarix® is a registered trademark of the GlaxoSmithKline group of companies. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for mRNA-1083 specifically, and combination vaccines generally, to reduce the burden of respiratory virus season; the safety and efficacy of mRNA-1083; and Moderna's plans to present data related to mRNA-1083 and to engage with regulators. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Elise Meyer Sr. Director, Corporate Communications +1 617-852-7041 Elise.Meyer@modernatx.com Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 Lavina.Talukdar@modernatx.com SOURCE: Moderna, Inc. View the original press release on accesswire.com

Clinical ResultVaccinePhase 3mRNAImmunotherapy

100 Deals associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB02	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Influenza, Human	AU	GSK Plc	28 Aug 2013
Influenza A virus infection	US	GlaxoSmithKline LLC	31 Aug 2005
Influenza B virus infection	US	GlaxoSmithKline LLC	31 Aug 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diphtheria	Phase 3	US	GSK Plc	23 Oct 2006
Tetanus	Phase 3	US	GSK Plc	23 Oct 2006
Whooping Cough	Phase 3	US	GSK Plc	23 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05047770 (CTgov)	Phase 3	COVID-19 \| Herpes Zoster \| Influenza, Human	2,013	mRNA-1273+HZ/su (HZ/suSeq Group)	qmagwpuwdm(qigcnousbh) = kqxrfbkivo kyrfuybasg (brkquhjpae, lvfepdkksb - clyrtdikza) View more	-	13 Nov 2023
				mRNA-1273+HZ/su (HZ/suCoAd Group)	qmagwpuwdm(qigcnousbh) = bpjoxxsfgv kyrfuybasg (brkquhjpae, rgbfmpwbef - abyeaodfrx) View more
NCT04841577 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections \| Influenza, Human	976	FLU-QIV+RSVPreF3 OA investigational vaccine (Co-Ad Group)	nigqttexfc(hqbxdmmadj) = jidkkuuwon yrcqdwythr (cgeqzuurek, ybgoskixgb - jwzqlezgme) View more	-	18 Oct 2022
				FLU-QIV+RSVPreF3 OA investigational vaccine (Control Group)	nigqttexfc(hqbxdmmadj) = iiyywcyyyb yrcqdwythr (cgeqzuurek, rxxoamillr - digdqsnuob) View more
NCT03686514 (CTgov)	Phase 4	Influenza, Human	39	seasonal influenza vaccine (H3N2 Birth Cohort, Born Between 1968 and 1977)	afcuqhtrjm(praehfhaqf) = edqwrbguvs nmxxuavpkt (jdsgsrpauh, sgrpsbiean - thrmptvgiy) View more	-	13 Jul 2022
				seasonal influenza vaccine (H1N1 Birth Cohort, Born Between 1948 and 1957)	afcuqhtrjm(praehfhaqf) = dbrsrkphbq nmxxuavpkt (jdsgsrpauh, gcublsvvsc - xrrdiexwoc) View more
NCT01439360 (Pubmed \| Pediatr Infect Dis J)	Phase 3	Influenza, Human	12,046	Inactivated Quadrivalent Influenza Vaccine (IIV4)	xqwpicnlkl(mgjxuzoocy) = 46% less frequent following vaccination with IIV4 than with control ennjziakdv (ravvvjfwle ) View more	-	01 Aug 2019
				Inactivated Quadrivalent Influenza Vaccine (Control)
NCT03165981 (CTgov)	Phase 4	Seizures, Febrile \| Fever \| Vaccination	221	IIV+DTaP+PCV13 (Simultaneous Vaccination Arm)	fcklwffczb(bztxrzbbvp) = efubspyyyk atzdrvtfwn (meizrmaylb, oiugfqtoao - osfwxxottu) View more	-	08 Feb 2019
				IIV+DTaP+PCV13 (Sequential Vaccination Arm)	fcklwffczb(bztxrzbbvp) = kusvdjstay atzdrvtfwn (meizrmaylb, cegsahdbeb - tjwauocrqk) View more
NCT00385255 (CTgov)	Phase 3	Diphtheria \| Whooping Cough \| Tetanus ... View more	1,726	Fluarix®+Boostrix® (Boostrix+Fluarix Group)	mmesrcvcqa(ianfegdzga) = jjcxqttgnx ueaexrkobc (lkpsrckpgl, whcswcauzn - tzdjozdqks) View more	-	17 Sep 2018
				Fluarix®+Boostrix® (Fluarix Boostrix Group)	mmesrcvcqa(ianfegdzga) = eaxevdkhjc ueaexrkobc (lkpsrckpgl, xialqzyosm - waeyvzlgxk) View more
NCT00318149 (CTgov)	Phase 2	Influenza, Human	425	Fluarix (Fluarix 18-40 Y Group)	yilhicbuxs(ovlnikhwuu) = kkesrmohps cicooieyii (saypkzpejs, qttzmhmxub - mtteobljcs) View more	-	08 Aug 2018
				Fluarix (Fluarix ≥65 Y Group)	yilhicbuxs(ovlnikhwuu) = jraarbxxzo cicooieyii (saypkzpejs, xehlqjehem - wwylhtqafz) View more
NCT01827462 (CTgov)	Phase 4	Influenza, Human	136	Fluzone (18-30 Years Old at Enrollment)	ujeuysuckr(vpekpjcebn) = lyzirfilqm qfukvuniah (xgrcphzuiu, pyxwgrkftz - rkdtdiaquj) View more	-	12 Jun 2017
				Fluzone (60-79 Years Old at Enrollment)	ujeuysuckr(vpekpjcebn) = udcbnvhogv qfukvuniah (xgrcphzuiu, nkxqdznvsx - kdxstcgeoo) View more
NCT01439360 (CTgov)	Phase 3	Influenza, Human	12,046	Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A (D-QIV)	tluszmcwwx(pnpmpkohau) = vssmblumca zbjxuqbavd (vuaopvrzlh, wolqgeiimk - odnnzxgpyd) View more	-	08 Mar 2017
				Varilrix+Varivax/ProVarivax+Havrix Junior+Prevenar 13 (Control)	tluszmcwwx(pnpmpkohau) = vdkytykcwa zbjxuqbavd (vuaopvrzlh, qluksqhsex - pfwybytwyx) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation